Costing of Paediatric Treatment alongside Clinical Trials under Low Resource Constraint Environments: Cotrimoxazole and Antiretroviral Medications in Children Living with HIV/AIDS
Table 3
Descriptive statistics of respondents: CHAP cohort.
(a)
Age (months)
CD4 count
CD4 percent
Weight (kg)
Descriptive statistics at commencement of CHAP trial
Mean
66
585
12
17
Median
57
449
11
16
Range
178
5422
54
38
Minimum
0
4
0
2
Maximum
178
5426
55
39
Progression of descriptive statistics at 48–72 weeks after initiation of cotrimoxazole
Mean
73
599
14
16
Median
64
601
13
14
Range
177
1813
58
33
Minimum
0
22
0
6
Maximum
177
1835
58
39
Descriptive statistics at commencement of CHAP trial
Mean
46
694
14
13
Median
38
587
13
11
Range
173
3288
56
27
Minimum
6
2
0
4
Maximum
179
3290
57
31
(b)
Weight (kg)
Age (months)
CD4 count
CD4 percent
Descriptive statistics at commencement of CHAPAS trial
Mean
15
6
550
13
Median
15
5.7
375
12
Range
22.8
14.7
3700
38
Minimum
3.2
0.2
2
0
Maximum
26
14.9
3702
38
Descriptive statistics at 72–96 weeks of ARV initiation in CHAPAS trial
